Abstract
Selecting lncRNAs for directed therapy with bioactive peptides and chemotherapy drugs may be an effective approach to treating gastric cancer (GC). We show genome-scale identification and characterization of differentially expressed lncRNAs in GC cells treated with a novel anti-cancer bioactive peptide (ACBP) and the chemotherapy drug oxaliplatin (ASLB). A total of 17,897 lncRNAs were identified through pairwise comparison, including 2,074 novel lncRNAs. Of those, 1,386 lncRNAs were differentially expressed (over 1.5-fold change vs. control, q-value < 0.05) in response to ACBP and ASLB treatment. These included 914 upregulated and 472 downregulated lincRNAs. Functional annotation of these lncRNAs through Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis revealed they activate metabolic pathways and protein-binding processes. Moreover, suppression of the DNA replication process and upregulation of AMP-activated protein kinase (AMPK) signaling in MKN45 cells exposed to ACBP alone or in combination with ASLB was predicted by hierarchical clustering analysis. By providing new insight into the transcriptomic effects of ACBP and ASLB in GC cells, these results provide the first evidence of ACBP inhibition of lincRNAs and may provide new mechanisms of action for ACBP and ASLB.
Highlights
Gastric cancer (GC) is one of the major causes of cancer deaths around the world
We show genomescale identification and characterization of differentially expressed Long noncoding RNAs (lncRNAs) in gastric cancer (GC) cells treated with a novel anti-cancer bioactive peptide (ACBP) and the chemotherapy drug oxaliplatin (ASLB)
Twelve MKN45 GC cell samples exposed to ACBP and ASLB, alone or in combination, were analyzed [16]
Summary
Gastric cancer (GC) is one of the major causes of cancer deaths around the world. In China, the annual mortality of GC is estimated to be as high as 16 per 100,000 population, with GC the leading cause of death among malignant tumors [1]. GC remains a leading cause of death, a major economic burden, and a severe hindrance to patient quality of life. Cell growth inhibitory effects from ASLB treatment were observed in many cancer cell lines and tumors, including those that are primarily resistant to cisplatin (CDDP) and carboplatin [3, 4]. In the treatment of GC patients, ASLB is frequently used because of its lack of nephrotoxicity or its low druginduced ototoxicity [5]. The side effects of ASLB chemotherapy for GC often result in poor quality of life
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
